Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial - PubMed
8 hours ago
- #NMOSD
- #ravulizumab
- #rituximab
- Post hoc analysis of CHAMPION-NMOSD trial evaluated ravulizumab's safety and efficacy in AQP4-Ab+ NMOSD patients with or without prior rituximab (RTX) exposure.
- Patients were stratified into RTX-naïve and RTX-exposed groups, with 36.2% having prior RTX exposure.
- No adjudicated relapses occurred during ravulizumab treatment, showing sustained disease control in both groups.
- Common treatment-emergent adverse events (TEAEs) included COVID-19, headache, UTIs, and upper respiratory infections, with UTIs more frequent in RTX-exposed patients.
- Safety profiles were manageable and similar between RTX-exposed and RTX-naïve groups.